TradeWins Inside Trading Newsletter

November 11, 2020

Trading Options With a Directional Bias: Part 2

Wednesday, November 18th
4:30 pm EST / 1:30 pm PST

In part 2 of Keith Harwood's series on trading options with a directional bias, he will do a deep dive on trading a technical edge with a focus on Option Vega (the Option's risk exposure to a change in the market's expected future movement of the stock).

Using technical setups can often lead to strong trading concepts that can and should focus on specific Options Greeks - in particular, the risks associated with an Option include passage of time, changes in price, and changes in implied volatility.

Keith will explain the technical setups he's looking for to employ a Vega-focused options trading strategy, the way that he applies a Vega-focused options trading strategy to those setups, and the many reasons why people shouldn't forget about the impact of the other Greeks when applying this type of strategy.

Save your spot today, as all attendees will receive a FREE COPY of Keith's Whitepaper on Options Trading!

Can't make the webinar, but want to learn more about Keith and his products? Click Here Now.

Some of the Top “Blood in the Streets” Opportunities to Consider by Ian Cooper

Market Sense by Lee Gettess

Range Expansion Index and DeMarker Indicator by Thomas DeMark

KeyPoint Market Daily by Joe Duffy

PULSE Options Weekly Newsletter by Chris Verhaegh

TradeWins Author Team

Tomorrow, you could begin doubling your account every single month starting with one letter.

The letter will come from a 20-year trading professional named Ian Cooper. He says, “In 2017, following my trades you would be doubling even tripling your account some months. Let me show you how.”

He will show you exactly what to do... and he’ll give you the blueprint for just $1.

Inside Trading Newsletter

Webinars

Videos

Trading Strategy

Options

Futures

Forex

Day Trading

Subscription Services

E-Books

Customer Satisfaction Survey 2020

Some of the Top “Blood in the Streets” Opportunities to Consider
by Ian Cooper

Over the last few months, the pandemic crippled the economy, destroying top stocks.

However, with a potential vaccine, those stocks may now be great “blood in the streets” opportunities. All on news Pfizer just said its COVID-19 vaccine is 90% effective.

“Amazing news from Pfizer with 90% efficacy. This hopefully is the beginning of the end of our fight against Covid,” Peter Boockvar, chief investment officer at Bleakley Advisory Group, said, as quoted by CNBC.

Plus, as noted by Pfizer Chairman and CEO Albert Bourla:

“It is a great day for science. It is a great day for humanity when you realize your vaccine has 90% effectiveness. That’s overwhelming,” Bourla said on CNBC. “You understand that the hopes of billions of people and millions of businesses and hundreds of governments that were felt on our shoulders, now... I think we can see light at the end of the tunnel.”

That being the case, here are some of the top opportunities to consider.

Top Opportunity No. 1 – Vaccine Stocks

While these don’t really fit the “blood in the streets” mold, these are two “must own” stocks moving forward. This includes Pfizer (PFE) and BioNTech (BNTX) – both of which are rocketing higher on news their vaccine is 90% effective.

Lee Gettess is a top trader who is excited to bring you his video newsletter. Each week, Lee will share his predictions on what he anticipates from the bond and S&P markets.

Watch Video

Range Expansion Index and DeMarker Indicator
by Thomas DeMark

I show you here two indicators that I created and have used for some time: (1) the Range Expansion Index (REI) and (2) the DeMarker indicator. I offer both as alternatives to the many widely followed publicly traded indicators. The REI and the DeMarker have been designed to identify price exhaustion areas that generally correspond with price peaks and troughs.

Range Expansion Index (REI)

I have always been suspicious of the indicators commonly used by traders. I believed that universal usage and acceptance effectively canceled the benefits that could be derived from any of them.

Joe Duffy’s KeyPoint Market Daily
November 11, 2020

Elite Wall Street trader, Joe Duffy, is allowing a limited group of future-elite investors into his masterful daily trades at thousands of dollars less than what others charge.

When you join today for $1, the first month you'll receive:

Joe Duffy’s daily video newsletter with updates on what's happening in the markets that very day. Rather than watch talking heads for hours on cable, I'll get you up to speed in minutes.

You get weekend updates where I delve more into 'bigger picture' looks at the marketplace. Videos are illustrative, instructive, concise, and un-hedged. No double talk here.

And much, much more!

Check out his most recent video here:

PULSE Options Weekly Newsletter
by Chris Verhaegh

First Things First

Before I discuss possibly the biggest event on the Calendar next week I want to point out that Earnings Season is on the downhill slope. Meaning that most of the major companies have already released their Earnings.

Below are a handful of the stocks releasing their Earnings this week, which we find interesting. There are only a half-dozen stocks listed below and only four of them are members of the S&P 500.

Monday, November 9
Before the Open: Aurora Cannabis (ACB), McDonalds (MCD) - #37
After the Close: Beyond Meat (BYND)

Thursday, November 12
After the Close: Applied Materials (AMAT) - #102, Cisco Systems (CSCO) - #38, Disney (DIS) - #20

www.tradewins.com

© Copyright 2020 TradeWins.com. All rights reserved.
TradeWins Publishing, 22C New Leicester Hwy, #117, Asheville, NC 28806
Email: support@iss-trading.com | Phone: 888-233-1431 | Fax: 888-258-4938

PLEASE READ: Auto-trading, or any broker or advisor-directed type of trading, is not supported or endorsed by TradeWins. For additional information on auto-trading, you may visit the SEC’s website: All About Auto-Trading, TradeWins does not recommend or refer subscribers to broker-dealers. You should perform your own due diligence with respect to satisfactory broker-dealers and whether to open a brokerage account. You should always consult with your own professional advisers regarding equities and options on equities trading.

1) The information provided by the newsletters, trading, training and educational products related to various markets (collectively referred to as the “Services”) is not customized or personalized to any particular risk profile or tolerance. Nor is the information published by TradeWins Publishing (“TradeWins”) a customized or personalized recommendation to buy, sell, hold, or invest in particular financial products. The Services are intended to supplement your own research and analysis.

2) TradeWins’ Services are not a solicitation or offer to buy or sell any financial products, and the Services are not intended to provide money management advice or services.

3) Past performance is not necessarily indicative of future results. Trading and investing involve substantial risk. Trading on margin carries a high level of risk, and may not be suitable for all investors. Other than the refund policy detailed elsewhere, TradeWins does not make any guarantee or other promise as to any results that may be obtained from using the Services. No person subscribing for the Services (“Subscriber”) should make any investment decision without first consulting his or her own personal financial adviser, broker or consultant. TradeWins disclaims any and all liability in the event anything contained in the Services proves to be inaccurate, incomplete or unreliable, or results in any investment or other loss by a Subscriber.

4) You should trade or invest only “risk capital” – money you can afford to lose. Trading stocks and stock options involves high risk and you can lose the entire principal amount invested or more.

5) All investments carry risk and all trading decisions made by a person remain the responsibility of that person. There is no guarantee that systems, indicators, or trading signals will result in profits or that they will not produce losses. Subscribers should fully understand all risks associated with any kind of trading or investing before engaging in such activities.

6) Some profit examples are based on hypothetical or simulated trading. This means the trades are not actual trades and instead are hypothetical trades based on real market prices at the time the recommendation is disseminated. No actual money is invested, nor are any trades executed. Hypothetical or simulated performance is not necessarily indicative of future results. Hypothetical performance results have many inherent limitations, some of which are described below. Also, the hypothetical results do not include the costs of subscriptions, commissions, or other fees. Because the trades underlying these examples have not actually been executed, the results may understate or overstate the impact of certain market factors, such as lack of liquidity. Simulated trading services in general are also designed with the benefit of hindsight, which may not be relevant to actual trading. In addition, hypothetical trading does not involve financial risk, and no hypothetical trading record can completely account for the impact of financial risk of actual trading. TradeWins makes no representations or warranties that any account will or is likely to achieve profits similar to those shown.

7) No representation is being made that you will achieve profits or the same results as any person providing testimonial. No representation is being made that any person providing a testimonial is likely to continue to experience profitable trading after the date on which the testimonial was provided, and in fact the person providing the testimonial may have experienced losses.

8) The author experiences are not typical. The author is an experienced investor and your results will vary depending on risk tolerance, amount of risk capital utilized, size of trading position and other factors. Certain Subscribers may modify the author methods, or modify or ignore the rules or risk parameters, and any such actions are taken entirely at the Subscriber’s own election and for the Subscriber’s own risk.